South Korea approves Celltrion's COVID-19 treatment for use

Celltrion

17/09/2021 09:24

SEOUL, Sept 17 (Reuters) - South Korea on Friday approved
drugmaker Celltrion Inc's  068270.KS  antibody COVID-19
treatment for infected adults in high-risk groups or those with
severe symptoms. 
    Phase III clinical trials showed that the treatment
significantly reduced deterioration of COVID-19 symptoms to
severe levels and shortened recovery, the Ministry of Food and
Drug Safety said in a statement on Friday. 
    The treatment lowered the rate of high-risk patients
developing severe symptoms by 72% and shortened recovery by 4.12
days, the ministry said. 
    Celltrion said in a separate regulatory filing it plans to
apply for emergency use approval and permission for the
treatment from each country through continuous discussions with
each regulatory agency. 
    Celltrion shares closed up 3.2% on Friday, compared with a
0.3% rise in the wider market  .KS11 .
    
    

 (Reporting by Joyce Lee; editing by Jason Neely)
 ((joyce.lee@tr.com;))